Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Doxycycline Hyclate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Doxycycline Hyclate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute on Drug Abuse | National Institute of Mental Health | National Institutes of Health | Florida State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VIC-1911,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : VITRAC Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : VIC-1911,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : VITRAC Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Divalproex Sodium,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : US Department of Defense | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : Divalproex Sodium,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : US Department of Defense | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Divalproex Sodium,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : US Department of Defense | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : Divalproex Sodium,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : US Department of Defense | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TMB-365,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : TaiMed Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 22, 2019
Lead Product(s) : TMB-365,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : TaiMed Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibalizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : TaiMed Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 12, 2019
Lead Product(s) : Ibalizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : TaiMed Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PPV-23,PCV-10
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 23, 2016
Lead Product(s) : PPV-23,PCV-10
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibalizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : TaiMed Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 14, 2016
Lead Product(s) : Ibalizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : TaiMed Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferrous Gluconate,Inapplicable
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Strategies to Reduce Iron Deficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 19, 2014
Lead Product(s) : Ferrous Gluconate,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lamivudine,Zidovudine,Efavirenz,Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2012
Lead Product(s) : Lamivudine,Zidovudine,Efavirenz,Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable